These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31942414)

  • 1. Evaluation of the JAK2V617F Mutational Burden in Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Single-center Experience.
    Popova-Labachevska M; Panovska-Stavridis I; Eftimov A; Kapedanovska NA; Cevreska L; Ivanovski M; Ridova N; Trajkova S; Dimovski AJ
    Balkan J Med Genet; 2019 Dec; 22(2):31-36. PubMed ID: 31942414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden.
    Ferdowsi S; Ghaffari SH; Amirizadeh N; Azarkeivan A; Atarodi K; Faranoush M; Toogeh G; Shirkoohi R; Vaezi M; Maghsoodlu M; Alimoghaddam K; Ghavamzadeh A; Teimori Naghadeh H
    Int J Hematol Oncol Stem Cell Res; 2016 Apr; 10(2):70-8. PubMed ID: 27252806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of
    Yönal-Hindilerden İ; Şahin E; Hindilerden F; Dağlar-Aday A; Nalçacı M
    Turk J Haematol; 2023 Aug; 40(3):174-182. PubMed ID: 37584526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of
    Wu S; Luo P; Rouzi T; Yu Y; Xiong B; Wang Y; Zuo X
    Cancer Control; 2023; 30():10732748231163648. PubMed ID: 36895113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.
    Şahin E; Yönal-Hindilerden İ; Hindilerden F; Aday A; Nalçacı M
    Turk J Med Sci; 2022 Feb; 52(1):150-165. PubMed ID: 34482679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
    Chen P; Ouyang J; Liang J; Yu X; Huang B
    Clin Lab; 2016 Aug; 62(8):1477-1481. PubMed ID: 28164603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms.
    Yonal-Hindilerden I; Daglar-Aday A; Akadam-Teker B; Yilmaz C; Nalcaci M; Yavuz AS; Sargin D
    J Clin Med Res; 2015 Mar; 7(3):161-70. PubMed ID: 25584101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Blood Res; 2013 Jun; 48(2):128-32. PubMed ID: 23826582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.
    Yonal-Hindilerden I; Daglar-Aday A; Akadam-Teker B; Yilmaz C; Nalcaci M; Yavuz AS; Sargin D
    J Blood Med; 2015; 6():157-75. PubMed ID: 26082670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
    Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
    Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
    Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.